Discovery of BMS-986144, a Third-Generation, Pan-Genotype NS3/4A Protease Inhibitor for the Treatment of Hepatitis C Virus Infection

The discovery of
a pan-genotypic hepatitis C virus (HCV) NS3/4A protease inhibitor
based on a P1–P3 macrocyclic tripeptide motif is described.
The all-carbon tether linking the P1–P3 subsites of 21 is functionalized with alkyl substituents, which are shown to effectively
modulate both potency and absorption, distribution, metabolism, and
excretion (ADME) properties. The CF3Boc-group that caps
the P3 amino moiety was discovered to be an essential contributor
to metabolic stability, while positioning a methyl group at the C1
position of the P1′ cyclopropyl ring enhanced plasma trough
values following oral administration to rats. The C7-fluoro, C6-CD3O substitution pattern of the P2* isoquinoline heterocycle
of 21 was essential to securing the targeted potency,
pharmacokinetic (PK), and toxicological profiles. The C6-CD3O redirected metabolism away from a problematic pathway, thereby
circumventing the time-dependent cytochrome P (CYP) 450 inhibition
observed with the C6-CH3O prototype.